128 related articles for article (PubMed ID: 8874204)
1. Modulation of in vitro and in vivo T-cell responses by transferrin-gallium and gallium nitrate.
Drobyski WR; Ul-Haq R; Majewski D; Chitambar CR
Blood; 1996 Oct; 88(8):3056-64. PubMed ID: 8874204
[TBL] [Abstract][Full Text] [Related]
2. Modulation of lymphocyte proliferation and immunoglobulin production by transferrin-gallium.
Chitambar CR; Seigneuret MC; Matthaeus WG; Lum LG
Cancer Res; 1989 Mar; 49(5):1125-9. PubMed ID: 2537143
[TBL] [Abstract][Full Text] [Related]
3. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
[TBL] [Abstract][Full Text] [Related]
4. Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid HL60 and lymphoid CCRF-CEM leukaemic cells.
Ul-Haq R; Chitambar CR
Biochem J; 1993 Sep; 294 ( Pt 3)(Pt 3):873-7. PubMed ID: 8379943
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of interleukin-10 and inhibition of alloantigen responses by transferrin and transferrin-derived glycans.
Lesnikova M; Lesnikov V; Arrighi S; Kistler G; Pierpaoli W; Deeg HJ
J Hematother Stem Cell Res; 2000 Jun; 9(3):381-92. PubMed ID: 10894360
[TBL] [Abstract][Full Text] [Related]
6. Transferrin receptor-mediated suppression of in vitro hematopoiesis by transferrin-gallium.
Chitambar CR; Craig A; Ash RC
Exp Hematol; 1989 Jun; 17(5):418-22. PubMed ID: 2714421
[TBL] [Abstract][Full Text] [Related]
7. Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.
Nakamura A; Sone S; Nabioullin R; Sugihara K; Munekata M; Nishioka Y; Nii A; Ogura T
Clin Exp Immunol; 1993 Apr; 92(1):174-9. PubMed ID: 8467561
[TBL] [Abstract][Full Text] [Related]
8. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.
Chitambar CR; Matthaeus WG; Antholine WE; Graff K; O'Brien WJ
Blood; 1988 Dec; 72(6):1930-6. PubMed ID: 3058232
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hemoglobin production by transferrin-gallium.
Chitambar CR; Zivkovic Z
Blood; 1987 Jan; 69(1):144-9. PubMed ID: 3790721
[TBL] [Abstract][Full Text] [Related]
11. Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells.
Chitambar CR; Sax D
Blood; 1992 Jul; 80(2):505-11. PubMed ID: 1627803
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier.
Townsend RM; Briggs C; Marini JC; Murphy GF; Korngold R
Blood; 1996 Oct; 88(8):3038-47. PubMed ID: 8874202
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.
Chouaib S; Welte K; Mertelsmann R; Dupont B
J Immunol; 1985 Aug; 135(2):1172-9. PubMed ID: 2989362
[TBL] [Abstract][Full Text] [Related]
14. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice.
Drobyski WR; Vodanovic-Jankovic S; Klein J
J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of placental-eluted gamma globulin and its immunosuppressive effect in vitro and in vivo].
Liu F; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):529-34. PubMed ID: 16800936
[TBL] [Abstract][Full Text] [Related]
16. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
19. Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process.
Richardson DR
Biochim Biophys Acta; 2001 Apr; 1536(1):43-54. PubMed ID: 11335103
[TBL] [Abstract][Full Text] [Related]
20. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
Streeter PR; Zhang X; Tittle TV; Schön CN; Weinberg AD; Maziarz RT
Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
